Contact Us Careers Register
Coherent Market Insights

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market to Surpass US$ 2,075.34 Million by 2027

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market to Surpass US$ 2,075.34 Million by 2027 - Coherent Market Insights

Publish In : Nov 23, 2020

Report ID : CMI4269

Category : Pharmaceutical

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market to Surpass US$ 2,075.34 Million by 2027

Global Community-acquired Bacterial Pneumonia  (CABP) Treatment Drugs Market, by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Launch of novel products by market players to augment the market growth

Key players in the market are focused on ‘regulatory product approval of novel products to address the critical unmet needs of patients. For instance, in August 2019, Nabriva Therapeutics, a spinoff of Novartis AG, received approval for Xenleta (lefamulin) by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP) in adults. The drug has also gained the U.S. FDA’s Qualified Infectious Disease Product (QIDP) designation and is available in the U.S. market.

Moreover, increasing incidence of pneumococcal disease is expected to drive the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, pneumococcal pneumonia causes around 150,000 hospitalizations every year, which surges the market progression in the U.S. Additionally, children, as well as elderly, are at a higher risk of getting infected by pneumococcal disease, owing to the weak immune system. Thus, increasing cases of pneumonia across the globe will propel the community-acquired bacterial pneumonia (CABP) treatment drugs market growth.

Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 30.6 million infected individuals worldwide as of 21st September 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another.

Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds which are used for manufacturing drugs such as community-acquired bacterial pneumonia (CABP) treatment drugs, which can hamper the market growth in the near future.

Browse 42 Market Data Tables and 26 Figures spread through 188 Pages and in-depth TOC on “Community-acquired Bacterial Pneumonia  (CABP) Treatment Drugs Market - by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global Forecast to 2027”

To know the latest trends and insights prevalent in the global community-acquired bacterial pneumonia (CABP) treatment drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/community-acquired-bacterial-pneumonia-treatment-drugs-market-4269

Key players in the market are focusing on developing and launching products for the treatment of community acquired bacterial pneumonia (CABP). For instance, in February 2019, Paratek Pharmaceuticals, Inc. a biopharmaceutical company commercially launched NUZYRA (omadacycline), a modernized tetracycline for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI) in the U.S.

Key Takeaways of the Global Community-acquired Bacterial Pneumonia  (CABP) Treatment Drugs Market:

  • The global community-acquired bacterial pneumonia (CABP) treatment drugs market is expected to exhibit a CAGR of 7.2% during the forecast period, owing to increasing incidence of community-acquired bacterial pneumonia, increasing R&D of community acquired bacterial pneumonia treatment products, and product launches. For instance, according to the Global Burden of Disease Study, an article published in the National Center for Biotechnology Information (NCBI) in November 2019, reports that globally, incidence of pneumonia is estimated to be between 1.5 and 14.0 cases per 1,000 person.
  • Among drug class, pleuromutilin antibiotic segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, owing to its potent activity against bacteria
  • Among dose form, tablet segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, as they potentially saves cost in the treatment.
  • Among route of administration, oral segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, as their variable penetration to different target sites of infection, drug solubility, and extent of protein binding determines the strong effectiveness.
  • Among distribution channel, hospital pharmacies segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, as majority of the community-acquired bacterial pneumonia patients are registered at hospitals.
  • Key players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market include Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.

ABOUT US:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

CONTACT US:

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

PHONE:

UK: +44-203-957-8553 / +44-203-949-5508

US: +1-252-477-1362

AUS: +61-8-7924-7805

INDIA: +91-848-285-0837

Email: [email protected]

Follow Us: LinkedIn | Twitter

Need more?

Speak to our analyst to understand how this research was put together
Add more segments or countries to the scope as part of free customization
Understand how this report can have a direct impact on your revenue

  • Supplier Analysis
  • Value Chain Analysis
  • Demand Analysis
  • Customer Intelligence
  • Trade Analysis
  • Pricing Analysis

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo

LogoCredibility and Certifications

Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

Reliability and Reputation

860519526

Reliability and Reputation
ISO 9001:2015

9001:2015

ISO 27001:2022

27001:2022

Reliability and Reputation
Reliability and Reputation
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Enquiry Icon Contact Us